We thank Professor Ka Leung Cheuk for his interest in our article and for the opportunity to further discuss some controversial aspects of the management of relapsed pediatric ALL, including the use of allogeneic hematopoietic cell transplantation (allo-HCT).
Concern was raised by Professor Ka Leung Cheuk over our recommendation that allo-HCT be pursued after 1st marrow relapse (in CR2), rather than awaiting subsequent treatment failure. This concern arises from the fact that our analysis is based purely on comparing HCT outcomes between CR2 and CR3 patients and the potential biases associated with this type of analysis. Our suggestion that allo-HCT be considered in CR2 for both early and late marrow relapse B-ALL is not merely based on how poorly patients do when brought to HCT in CR3, but more importantly, is based on the seemingly inferior outcomes with intensive chemotherapy re-treatment without transplantation. [1] [2] [3] For instance, in our analysis, patients with an early marrow relapse treated with allo-HCT had a 5-year overall survival (OS) of 53%. 4 These results compare favorably to what has been described historically for patients receiving chemotherapy alone (5-year OS o30%).
1-3 Importantly, these results are consistent with other retrospective-comparison studies reporting superior outcomes for allo-HCT compared with chemotherapy in B-ALL patients with an early marrow relapse. [1] [2] [3] For the late marrow relapse patients transplanted in CR2, we report a 5-yr OS of 75%. These results appear to be superior to the expected survival rates of o45% when chemotherapy alone is given. [1] [2] [3] 5 Professor Ka Leung Cheuk comments that our recommendation to transplant all relapsed ALL patients in CR2 can only be directly proven using prospective randomized studies. We completely agree with this. In this regard, the Children's Oncology Group is currently randomizing late-relapsed B-ALL patients in CR2 to either chemotherapy or allo-HCT. Importantly, this study will only use matched related donors and, thus limit any conclusions regarding unrelated donors in this setting. As there have been no prospective clinical trials randomizing children with 2nd relapse (CR3) ALL to chemotherapy versus allo-HCT this also remains unresolved. However, in the meantime, studies such as ours may assist individuals in these difficult treatment decisions involving the utility of allo-HCT in the management of relapsed ALL.
There are a few other issues that should be clarified. In his letter, Professor Ka Leung Cheuk adds that selection bias might have occurred if differences existed in patient characteristics, including performance status between patients with a late marrow relapse in CR2 versus CR3. Although this potential exists, as stated in our report, there were no significant differences identified in multivariate analysis comparing patient characteristics based on CR status. In addition, all patients in our analysis received a myeloablative allo-HCT on institutional review board approved protocols that have rigid entry criteria, including performance status. Thus, performance status was similar between groups. As well, it was suggested that the degree of HLA matching might be worse in the late transplant group, as patients with well-matched donors might have been transplanted earlier. Although possible, it was not the case in our analysis and there was no significant difference in outcomes based on HLA-matching in our multivariate analysis. As well, we find it surprising that Professor Ka Leung Cheuk classifies our results 'spurious' and based on 'highly variable factors' into the late relapse CR2 and CR3 groups. We did not report (and could not identify) any significant differences in performance status, organ dysfunction, HLA-typing, CMV status, graft source, conditioning regimen or GVHD prophylaxis between these patient groups. This statement is suggested by Professor Ka Leung Cheuk based on the lack of significance in diseasefree survival between late relapse CR2 and CR3 patients in multivariate analysis, but was identified in univariate analysis. The inability of multivariate analysis to show a significant difference in disease-free survival is more likely an issue of statistical power, as our cohort is relatively small, rather than differences in patient characteristics that were not identified. Further it was stated that the biology of the leukemia changes with subsequent relapses and that the comparison between the two groups is not appropriate. Although we agree on this point, we also believe that this statement is precisely why allo-HCT should be pursued early, rather than later in these patients.
In conclusion, our report of favorable outcomes with allo-HCT for children with early and late marrow relapse B-ALL, as well as significantly improved survival when HCT is pursued in CR2 versus CR3 for late marrow relapse patients, are consistent with the current literature. We agree with the need for well-designed prospective clinical trials comparing allo-HCT with chemotherapy for children with ALL late marrow relapse. However, in the absence of such studies we stand by our recommendation that allo-HCT be considered for all patients in CR2 after B-ALL relapse.
